Abstract
Background and purpose: This study investigates the therapeutic potential of hIgDFc-Ig (DG), a novel biological agent that targets the IgD receptor (IgDR), in treating collagen-induced arthritis (CIA). The research focuses on DG's ability to modulate the B cell antigen-receptor (BCR) signaling pathway. Experimental approach: DBA1 mice were used to model CIA, receiving three doses of DG via intraperitoneal injection. Therapeutic efficacy was evaluated through clinical scoring, histopathology, flow cytometry, and molecular signaling analysis. The mechanism was further explored in vitro using the Daudi human B cell line. Key results: DG treatment significantly improved clinical symptoms and joint pathology in CIA mice. Mechanistically, DG inhibited BCR over-activation by increasing p-Lyn levels and disrupting the Syk-Btk interaction, leading to reduced NF-κB activation and lower immunoglobulin levels. Conclusion: DG acts as a promising immunomodulatory agent for rheumatoid arthritis by specifically regulating the BCR-Lyn-Syk-NF-κB signaling axis.
Introduction
Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by persistent joint inflammation and progressive bone destruction. B cells are central to RA pathogenesis, contributing through the production of autoantibodies and pro-inflammatory cytokines. While current B cell-depleting therapies like Rituximab are effective, they carry risks of severe immunosuppression. There is a critical need for therapies that can "re-tune" overactive B cells without total depletion. This study evaluates hIgDFc-Ig (DG), a fusion protein designed to competitively bind the IgD receptor (IgDR), as a novel immunomodulatory strategy.
Methods and Mechanism of Action
The researchers employed a combination of in vivo and in vitro models. DBA1 mice with collagen-induced arthritis (CIA) served as the primary disease model, while the Daudi human B cell line was used to dissect molecular pathways. DG works by competing with endogenous IgD for binding to the IgD receptor on the B cell surface. This competitive inhibition was visualized using immunofluorescence to track the spatial relationship between IgDR and the B cell receptor (BCR).
Key Results
Clinical and Pathological Improvement
DG administration resulted in a significant, dose-dependent reduction in the arthritis index and joint swelling in CIA mice. Histopathological examination confirmed that DG treatment mitigated synovial hyperplasia, inflammatory cell infiltration, and cartilage erosion. Furthermore, DG treatment normalized the proportions of memory B cells and plasma cells in the spleen and peripheral blood.
Functional Inhibition of B Cells
A primary outcome of DG treatment was the suppression of B cell over-activation. Functional assays measuring relative absorbance demonstrated that DG significantly lowered B cell activity compared to untreated CIA controls, with effects comparable to established therapies like Etanercept.
Molecular Signaling Regulation
The therapeutic effect of DG is mediated through the BCR-Lyn-Syk-NF-κB pathway. DG was found to increase the phosphorylation of Lyn (p-Lyn), a negative regulator of BCR signaling. This "molecular brake" subsequently inhibited the phosphorylation of Syk and Btk and prevented the nuclear translocation of NF-κB (p65). This signaling cascade suppression led to a marked decrease in the production of various immunoglobulins (IgG1, IgG2a, IgE), reducing the autoimmune burden.
Conclusion and Implications
This study demonstrates that hIgDFc-Ig (DG) is an effective therapeutic agent for collagen-induced arthritis. By targeting the IgD receptor and modulating the BCR-Lyn-Syk-NF-κB signaling pathway, DG provides a sophisticated method of controlling B cell-driven inflammation. This approach offers a potential advantage over total B cell depletion by selectively dampening pathogenic activation, making DG a promising candidate for future clinical development in rheumatoid arthritis.
Summary updated